Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (6): 709-714.doi: 10.12092/j.issn.1009-2501.2022.06.015

Previous Articles     Next Articles

Integrins targeting αv are used as drug targets for pulmonary fibrosis

LIU Nanyu1, YUE Hongmei1,2, SONG Peipei1, WEI Jifang1, WEI Yaqian1, XIE Yingying1, WANG Jiaqi1   

  1. 1The First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu, China; 2Department of Respiratory Medicine,the First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China
  • Received:2022-04-21 Revised:2022-05-10 Online:2022-06-26 Published:2022-07-08

Abstract: IPF is a chronic progressive interstitial lung disease of unknown etiology and poor prognosis, and despite receive treatment, most patients consideration are likely to progress or worsen. Integrins are heterodimer cell surface proteins that are promising therapeutic targets for intervention in pulmonary fibrosis. Alphav integrins are central to the development of fibrosis because they activate latent TGF-β, a known pro-fibrosis cytokine. The alphav subunit may form heterodimers with the β1, β3, β5, β6, or β8 subunits, one or more of which are essential for the development of pulmonary fibrosis, but their relative importance is unclear. This review summarizes the knowledge of the association of pulmonary fibrosis with alpha-val-integrins, as well as emerging preclinical studies and clinical trials of alpha-fibrosis inhibitors.

Key words: pulmonary fibrosis, alphav integrin, TGF-β, alphav integrin inhibitors

CLC Number: